Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4097012 | 0.68 | CYP19A1 (0.43) | MEN1MAPTMAPK1KMT2AUSP2 | |
| SCHEMBL4097016 | 0.68 | CYP19A1 (0.43) | MEN1MAPTMAPK1KMT2AUSP2 | |
| SCHEMBL4803440 | 0.62 | NOS2 (0.33) | USP2 | |
| SCHEMBL16628455 | 0.62 | ALK (0.34) | MEN1KMT2A | |
| SCHEMBL16628454 | 0.62 | ALK (0.34) | MEN1KMT2A | |
| SCHEMBL9296517 | 0.61 | ADRA2A (0.41) | MEN1MAPTMAPK1KMT2AUSP2 | |
| SCHEMBL15219995 | 0.56 | CES1 (0.50) | MEN1MAPTMAPK1KMT2AUSP2 | |
| SCHEMBL15622089 | 0.56 | ITGB3 (0.35) | — | |
| SCHEMBL31564075 | 0.54 | FFAR3 (0.38) | MEN1MAPTMAPK1KMT2A | |
| SCHEMBL3872610 | 0.53 | NOS2 (0.50) | USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409476-B1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | GILMORE JEREMY (GB) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | HTR1A, HTR5A, HTR1E | MEN1 1131/4885MAPT 2990/4885MAPK1 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.